Gynae BT 2017

BENEFIT FROM CONCOMITANT RADIOCHEMOTHERAPY

AUTHOR

RANDOMISATION ARMS STAGE

LOCOREGIONAL RECURRENCE

3 YEAR OVERALL SURVIVAL

RT + Cisplatin + HE RT+ HE

Bulky IB

9% 21% RR 0.51 (95% CI) 24.9% 30.4% RR 0.79 (90% CI)

83% 74% (p=0.008) 67% 57% (p=0.018) 65% 65% 47% (p=0.004) 75% 63% (p=0.004) 81% 71% (p=0.007) 69% 66% (p=0.42)

Keys et al N Engl J Med. 1999

RT + Cis/5-FU RT + HU

IIB,III, IVA

Whitney et al J Clin Oncol. 1999

RT + Cisplatin RT + Cis/5-FU+HU RT + HU

IIB,III, IVA

Not reported

Rose et al N Engl J Med. 1999 Morris et al N Engl J Med. 1999

RT + Cis/5-FU RT (pelvis + paraaortal)

IB-IVA (~70% IB-IIB in each group) IA2,IB, IIA

19% 35% RR 0.47 (95% CI)

HE + RT + Cis/5-FU HE + RT

5.5% 17%

Peters et al J Clin Oncol. 2000

RT+Cisplatin RT

IB-IVA Not reported

Pearcey et al J Clin Oncol. 2002